Cargando…

Treatment of Graves' Disease Associated With Severe Neutropenia

Severe neutropenia in newly diagnosed hyperthyroidism is a diagnostic and therapeutic dilemma since antithyroid drugs (ATDs) cannot be started if the absolute neutrophil count (ANC) is <1 x 10(9)/L. We report the case of a patient followed for hyperthyroidism associated with severe neutropenia tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Laidi, Soukaina, Motaib, Imane, Elamari, Saloua, Anajar, Said, Chadli, Asma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818315/
https://www.ncbi.nlm.nih.gov/pubmed/35154986
http://dx.doi.org/10.7759/cureus.21014
_version_ 1784645803907743744
author Laidi, Soukaina
Motaib, Imane
Elamari, Saloua
Anajar, Said
Chadli, Asma
author_facet Laidi, Soukaina
Motaib, Imane
Elamari, Saloua
Anajar, Said
Chadli, Asma
author_sort Laidi, Soukaina
collection PubMed
description Severe neutropenia in newly diagnosed hyperthyroidism is a diagnostic and therapeutic dilemma since antithyroid drugs (ATDs) cannot be started if the absolute neutrophil count (ANC) is <1 x 10(9)/L. We report the case of a patient followed for hyperthyroidism associated with severe neutropenia treated with dexamethasone and ATD. The patient was 51 years old and was hospitalized for hyperthyroidism with a thyroid stimulating hormone (TSH) level <0.005 (0.4-4) mUI/L, T4 at 415 (9.3-17.1) ng/L and T3 at 148 (2-4.4) pg/mL on Graves' disease (GD) confirmed by the TSH receptor antibodies at 38 IU/mL and scintigraphy, associated with neutropenia, with ANC at 0.4 x 10(9)/L. He was put on prednisolone 60 mg/day and propranolol 60 mg/day for three weeks without improvement. Faced with the association of hyperthyroidism and severe neutropenia, we could not start the ATD for fear of agranulocytosis; we put the patient on propranolol 60 mg and dexamethasone 6 mg with progressive degression resulting in a spectacular increase of ANC from 0.4 x 10(9)/L to 7.1 x 10(9)/L, which allowed us to start the ATD (carbimazole) at a dose of 30 mg, and then 50 mg, with monitoring of ANC and transaminases every 48 hours. Euthyroidism was achieved after 15 days. A curative treatment with radioactive iodine ablation was administered. Our patient did not respond to prednisolone but responded dramatically to dexamethasone; this leads us to consider using dexamethasone for the rapid preparation for radical treatment of patients with GD.
format Online
Article
Text
id pubmed-8818315
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88183152022-02-11 Treatment of Graves' Disease Associated With Severe Neutropenia Laidi, Soukaina Motaib, Imane Elamari, Saloua Anajar, Said Chadli, Asma Cureus Endocrinology/Diabetes/Metabolism Severe neutropenia in newly diagnosed hyperthyroidism is a diagnostic and therapeutic dilemma since antithyroid drugs (ATDs) cannot be started if the absolute neutrophil count (ANC) is <1 x 10(9)/L. We report the case of a patient followed for hyperthyroidism associated with severe neutropenia treated with dexamethasone and ATD. The patient was 51 years old and was hospitalized for hyperthyroidism with a thyroid stimulating hormone (TSH) level <0.005 (0.4-4) mUI/L, T4 at 415 (9.3-17.1) ng/L and T3 at 148 (2-4.4) pg/mL on Graves' disease (GD) confirmed by the TSH receptor antibodies at 38 IU/mL and scintigraphy, associated with neutropenia, with ANC at 0.4 x 10(9)/L. He was put on prednisolone 60 mg/day and propranolol 60 mg/day for three weeks without improvement. Faced with the association of hyperthyroidism and severe neutropenia, we could not start the ATD for fear of agranulocytosis; we put the patient on propranolol 60 mg and dexamethasone 6 mg with progressive degression resulting in a spectacular increase of ANC from 0.4 x 10(9)/L to 7.1 x 10(9)/L, which allowed us to start the ATD (carbimazole) at a dose of 30 mg, and then 50 mg, with monitoring of ANC and transaminases every 48 hours. Euthyroidism was achieved after 15 days. A curative treatment with radioactive iodine ablation was administered. Our patient did not respond to prednisolone but responded dramatically to dexamethasone; this leads us to consider using dexamethasone for the rapid preparation for radical treatment of patients with GD. Cureus 2022-01-07 /pmc/articles/PMC8818315/ /pubmed/35154986 http://dx.doi.org/10.7759/cureus.21014 Text en Copyright © 2022, Laidi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Laidi, Soukaina
Motaib, Imane
Elamari, Saloua
Anajar, Said
Chadli, Asma
Treatment of Graves' Disease Associated With Severe Neutropenia
title Treatment of Graves' Disease Associated With Severe Neutropenia
title_full Treatment of Graves' Disease Associated With Severe Neutropenia
title_fullStr Treatment of Graves' Disease Associated With Severe Neutropenia
title_full_unstemmed Treatment of Graves' Disease Associated With Severe Neutropenia
title_short Treatment of Graves' Disease Associated With Severe Neutropenia
title_sort treatment of graves' disease associated with severe neutropenia
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818315/
https://www.ncbi.nlm.nih.gov/pubmed/35154986
http://dx.doi.org/10.7759/cureus.21014
work_keys_str_mv AT laidisoukaina treatmentofgravesdiseaseassociatedwithsevereneutropenia
AT motaibimane treatmentofgravesdiseaseassociatedwithsevereneutropenia
AT elamarisaloua treatmentofgravesdiseaseassociatedwithsevereneutropenia
AT anajarsaid treatmentofgravesdiseaseassociatedwithsevereneutropenia
AT chadliasma treatmentofgravesdiseaseassociatedwithsevereneutropenia